

Research article

Open Access

Inflammation causes tissue-specific depletion of vitamin B₆En-Pei Chiang¹, Donald E Smith², Jacob Selhub³, Gerard Dallal⁴, Yi-Cheng Wang¹ and Ronenn Roubenoff⁵¹Department of Food Science and Biotechnology, National Chung Hsing University, Taichung, Taiwan²Comparative Biology Unit, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA³Vitamin Metabolism and Aging Laboratory (JS), New England Medical Center, Boston, MA, USA⁴Biostatistics Unit (GD), New England Medical Center, Boston, MA, USA⁵Nutrition, Exercise Physiology, and Sarcopenia Laboratory, New England Medical Center, Boston, MA, USACorresponding author: En-Pei Chiang, chiangisabel@nchu.edu.tw

Received: 4 May 2005 Revisions requested: 4 Jul 2005 Revisions received: 2 Aug 2005 Accepted: 15 Aug 2005 Published: 13 Sep 2005

Arthritis Research & Therapy 2005, **7**:R1254-R1262 (DOI 10.1186/ar1821)This article is online at: <http://arthritis-research.com/content/7/6/R1254>© 2005 Chiang *et al.*; licensee BioMed Central Ltd.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.**Abstract**

Previously we observed strong and consistent associations between vitamin B₆ status and several indicators of inflammation in patients with rheumatoid arthritis. Clinical indicators, including the disability score, the length of morning stiffness, and the degree of pain, and biochemical markers, including the erythrocyte sedimentation rate and C-reactive protein levels, were found to be inversely correlated with circulating vitamin B₆ levels. Such strong associations imply that impaired vitamin B₆ status in these patients results from inflammation. In the present study we examined whether inflammation directly alters vitamin B₆ tissue contents and its excretion *in vivo*. A cross-sectional case-controlled human clinical trial was performed in parallel with experiments in an animal model of inflammation. Plasma and erythrocyte and pyridoxal 5'-phosphate concentrations, urinary 4-pyridoxic acid excretion, and the activity coefficient of erythrocyte aspartate aminotransferase were compared

between patients and healthy subjects. Adjuvant arthritis was induced in rats for investigating hepatic and muscle contents as well as the urinary excretion of vitamin B₆ during acute and chronic inflammation. Patients with rheumatoid arthritis had low plasma pyridoxal 5'-phosphate compared with healthy control subjects, but normal erythrocyte pyridoxal 5'-phosphate and urinary 4-pyridoxic acid excretion. Adjuvant arthritis in rats did not affect 4-pyridoxic acid excretion or muscle storage of pyridoxal 5'-phosphate, but it resulted in significantly lower pyridoxal 5'-phosphate levels in circulation and in liver during inflammation. Inflammation induced a tissue-specific depletion of vitamin B₆. The low plasma pyridoxal 5'-phosphate levels seen in inflammation are unlikely to be due to insufficient intake or excessive vitamin B₆ excretion. Possible causes of decreased levels of vitamin B₆ are discussed.

Introduction

Vitamin B₆ deficiency results in adverse health consequences, including hyperhomocysteinemia [1] and possibly arteriosclerotic lesions [2]. We have reported that the degree of disease activity is associated with vitamin B₆ indices in patients with rheumatoid arthritis [3,4]. Bates and colleagues reported sub-optimal vitamin B₆ status in inflammatory conditions and in the acute-phase response in the elderly population [5]. These observations have attracted attention partly because vitamin B₆ deficiency and several markers of inflammation were both found to be independent risk factors for thrombosis [6,7]. Although several clinical trials and epidemiological studies have demonstrated the associations between vitamin B₆ and inflammatory diseases, the association between vitamin B₆ status and inflammatory markers has been contentious, and

the cause-effect relationship between these two has not been elucidated.

Pyridoxine deficiency increased the degree of paw edema by 54% in a rat model of inflammation; it was therefore suggested that pyridoxine deficiency might enhance inflammation [8]. However, in healthy middle-aged adults, B vitamin status does not seem to be a strong correlate of circulating levels of inflammatory markers [9]. In contrast, a low level of circulating vitamin B₆ was found to be associated with elevation of the inflammatory marker C-reactive protein independently of plasma homocysteine levels in the Framingham Heart Study cohort [10]. A recent study indicated that low plasma concentrations of pyridoxal 5'-phosphate are inversely related to major markers of inflammation and independently associated with

increased coronary artery disease in the Italian population [11]. Decreased vitamin B₆ status was also reported in patients after surgery and trauma [12]. In conditions with inflammation such as inflammatory bowel disease, low plasma levels of vitamin B₆ are commonly found, especially in patients with active disease [13]. In a recent study we observed strong and consistent associations between vitamin B₆ status and several indicators of inflammation in patients with rheumatoid arthritis [4]. Plasma pyridoxal 5'-phosphate was correlated with disease-related disability, morning stiffness, and degree of pain, C-reactive protein, serum albumin, and erythrocyte sedimentation rate [4].

The objective of the present study was to determine whether inflammation directly decreases the primary pools of vitamin B₆ metabolism and storage, and to examine whether inflammation alters the excretion of vitamin B₆ *in vivo*.

Materials and methods

Clinical trial

Study subjects

Thirty-three adults (aged at least 18 years) with rheumatoid arthritis were recruited from the Tufts University New England Medical Center Arthritis Center, Boston, as described previously [14]. Seventeen healthy control subjects, who did not differ in their age range or gender distribution from the subjects with rheumatoid arthritis, were recruited through advertisements in the greater Boston area. Study subjects were 18 to 80 years old. For the rheumatoid arthritis group, subjects had to fulfill the American College of Rheumatology criteria for rheumatoid arthritis [15]. The criteria for the classification of acute arthritis of rheumatoid include the following: (1) morning stiffness in and around the joints, lasting at least 1 hour before maximal improvement; (2) at least three joint areas simultaneously have had soft tissue swelling or fluid (not bony overgrowth alone) observed by a physician; (3) at least one area swollen of hand joints in a wrist, metacarpophalangeal, or proximal interphalangeal joint; (4) simultaneous involvement of the same joint areas (as defined in (2)) on both sides of the body; (5) rheumatoid nodules observed by a physician; (6) abnormal amounts of serum rheumatoid factor; (7) radiographic changes typical of rheumatoid arthritis on posteroanterior hand and wrist radiographs, which must include erosions or unequivocal bony decalcification localized in or most marked adjacent to the involved joints.

Written informed consent was obtained from all subjects in accordance with the regulations of the New England Medical Center/Tufts University Human Investigation Review Committee. Subjects with pregnancy, anemia (hemoglobin 10 mg/dL or lower), thrombocytopenia (platelet count 50,000/ μ L or lower), abnormal serum hepatic transaminase (serum aspartate aminotransferase or alanine aminotransferase at least 50 IU/L), renal insufficiency (serum creatinine at least 1.5 mg/dL), diabetes, cancer or use of oral contraceptive were excluded.

Thirteen of the 33 patients (39%) and 7 of the 17 controls (41%) were taking vitamin B6 or multivitamin supplements before enrollment. These subjects were asked to stop doing so for at least 2 months before their participation in the study.

Experimental protocol

This cross-sectional study was conducted in the New England Medical Center General Clinical Research Center. Before enrollment, each subject was examined by the study physician, and was screened by blood and urine analyses to ensure eligibility. Each subject was instructed to perform a 24-hour urine collection for measurement of 4-pyridoxic acid excretion. Patients taking methotrexate were asked to come in at least 24 hours after their weekly dose of the medicine to minimize any potential acute effect on laboratory outcomes. Urine specimens were kept at 4°C with no additive during the collection period. After completion of the 24-hour urine collection, subjects were asked to fast overnight for 12 hours. During the following morning, fasting blood was drawn into a tube containing EDTA for the determination of plasma pyridoxal 5'-phosphate, erythrocyte pyridoxal 5'-phosphate, erythrocyte aspartate aminotransferase activity coefficient, folate, and vitamin B₁₂. Blood was also collected for hematology and chemistry analyses. Each patient's blood specimens were kept on ice and were centrifuged within 15 min of the blood draw.

Animal model of inflammation

Animal

Thirty-six female 3-month-old Lewis rats were obtained from the National Institutes of Health. Animals were fed with the AIN93M diet during a 1-week washout period and during the experimental period. All animals were kept in individual mesh cages and acclimated to a 12-hour day/night cycle. The study protocol was approved by the Animal Care and Use Committee of National Chung Hsing University and of the Human Nutrition Research Center on Aging at Tufts University.

Induction of arthritis

After the washout period, animals of the same age and gender were sorted by body weight and assigned sequentially to the adjuvant arthritis or control groups (Table 1). Adjuvant arthritis was induced at baseline by injecting a single dose of *Mycobacterium butyricum* in mineral oil (complete Freund's adjuvant; 200 μ L per rat) [16] into the base of the tail at the baseline time-point. The age-matched, paired-fed control animals received a saline injection.

Pair-feeding protocol

After the induction of adjuvant arthritis, for each rat in the adjuvant arthritis group one control rat, matched for age and weight, received the same amount of food on the next day. This protocol minimized variations in body weight and in vitamin B₆ consumption due to different dietary intake.

Table 1**Changes in body weight in response to adjuvant arthritis in Lewis rats**

Group	Body weight (g)		
	Baseline	Day 21	Day 42
Adjuvant arthritis	275.4 ± 85.3	228.9 ± 71.4 (-16.9%)	214.1 ± 60.7 (-22.3%)
Control	268.3 ± 86.3	259.1 ± 77.5 (-3.4%)	262.1 ± 73.0 (-2.3%)

Data are shown as means ± SD. Percentage changes in body weight at each time point (compared with baseline) are shown in parentheses. Day 21 represents the acute inflammation condition; day 42 represents the chronic inflammation condition.

Sample collection

Fasting blood samples were collected from the orbital sinus vein of each rat under anesthesia at baseline. Plasma was separated immediately by centrifugation and stored at -80°C until analysis. Sixteen animals (eight control and eight arthritic rats) were killed 21 days after the adjuvant injection, reflecting the condition of acute inflammation. The rest were killed on day 42, reflecting the condition of chronic inflammation. Animals were killed by thoracotomy and exsanguinations after anesthesia. Blood, liver, and skeletal muscle were collected and stored at -80°C until analysis for pyridoxal 5'-phosphate concentration. On selected days (days reflecting baseline, peak inflammation, and chronic inflammation), each animal was kept in an individual metabolic cage, specifically designed for the 24-hour collection of urine. The excretion of urinary 4-pyridoxic acid and creatinine was subsequently measured.

Laboratory analyses

Blood hematology and chemistry analyses and urinalysis for human subjects were performed at the New England Medical Center Clinical Laboratory, Boston. For measurements of B vitamins, fasting blood was drawn from each human subject, and plasma was separated and stored at -80°C until analysis. Erythrocytes were washed three times with 0.9% saline and then an aliquot of packed erythrocytes was frozen before the measurement of erythrocyte aspartate aminotransferase [17]. The activity coefficient of erythrocyte aspartate aminotransferase was calculated by dividing pyridoxal 5'-phosphate-stimulated enzyme activity by the unstimulated activity. For pyridoxal 5'-phosphate analysis, the freshly washed erythrocytes were extracted with an equal volume of 10% (w/v) perchloroacetic acid. After centrifugation, the supernatants were stored at -70°C until analysis. Erythrocyte and plasma pyridoxal 5'-phosphate concentrations were assayed by a modification of the tyrosine decarboxylase enzymatic procedure of Camp and colleagues [18], in which a 20 µL aliquot of sample was precipitated with 80 µL of 5% (w/v) trichloroacetic acid for deproteinization. The erythrocyte pyridoxal 5'-phosphate results were expressed as nmol/L of packed erythrocytes at a hematocrit of 100%. The coefficient of variation (percentage of the mean) for the pyridoxal 5'-phosphate assay was 7.6% within assays and 5.7% between assays. Plasma folate, red blood cell folate, and plasma vitamin B₁₂ were measured with Quantaphase II B₁₂/Folate Radioassays (Bio-Rad; Hercules,

CA). The weight of each 24-hour urine specimen was measured; aliquots were taken and stored at -20°C until analysis. No preservatives were added to the 4-pyridoxic acid or creatinine aliquots. 4-Pyridoxic acid was measured by high-performance liquid chromatography after urine had been mixed with an equal volume of 5% trichloroacetic acid for deproteinization [19]. The HPLC consisted of a Hitachi L-7100 intelligent pump connected to an L-2480 fluorometric detector. The ranges for plasma pyridoxal 5'-phosphate and urinary pyridoxic acid were in good agreement with published results. The range of erythrocyte pyridoxal 5'-phosphate concentrations in our subjects was similar to that in a previous study by Heiskanen and colleagues [20].

Statistical analysis

Data were plotted so that they could be examined for normality before statistical analyses. Data for plasma pyridoxal 5'-phosphate and red blood cell folate levels in humans were log-transformed to achieve normal distributions, and the geometric means with the antilogarithm of the 95% confidence intervals are presented as results. Student's *t*-tests for independent samples were performed to determine whether there was a difference between patients with rheumatoid arthritis and controls in hematology measures, blood chemistry analyses, and vitamin profiles. For animal experiments, pooled Student's *t*-tests were performed to determine whether there was a difference between arthritic rats and matched control animals. All statistical analyses were performed with Systat 9.0 for Windows™ (SPSS, Chicago, IL).

Results**Demographic information**

Thirty-six patients with rheumatoid arthritis were recruited from a previous study [14]. In the present study, a further 17 healthy subjects were recruited as control subjects. Three subjects from the patient group dropped out because of inconvenience of the 24-hour urine collection. Clinical and demographic characteristics of the study subjects are shown in Table 2. There were no differences in age, height, or weight between patients and controls, indicating that the control subjects and the patients did not differ in their physical conditions except for the presence of rheumatoid arthritis. The average disease duration in patients with rheumatoid arthritis was 10.8 ± 6.7 (mean ± SD) years. While participating in the study, 21 patients were

Table 2**Characteristics of study subjects**

Characteristic	RA (n = 33)	Controls (n = 17)	P
Sex (F:M)	23:10	10:7	-
Age	53.5 ± 12.4	52.9 ± 15.7	NS
Height (cm)	167.3 ± 11.0	170.1 ± 8.6	NS
Weight (kg)	77.1 ± 21.1	74.9 ± 17.9	NS
Rheumatoid factor (IU/mL)	89.4 ± 76.1	< 20	<0.0001
Chemistry			
Urinary creatinine (g/24 h)	1.0 ± 0.4	1.2 ± 0.3	NS
Serum urea nitrogen (mg/dL)	13.2 ± 4.3	15.6 ± 3.0	<0.05
Albumin (g/dL)	3.9 ± 0.4	4.0 ± 0.4	NS
Serum AST (IU/L)	19.4 ± 9.8	21.9 ± 11.2	NS
Serum ALT (IU/L)	21.4 ± 4.5	23.9 ± 7.5	NS
Alkaline phosphatase (IU/L)	72.2 ± 19.6	57.2 ± 14.3	<0.01
Hematology			
White blood cell counts (/nL)	7.3 ± 3.0	5.5 ± 1.2	<0.01
Hematocrit (%)	38.0 ± 3.5	39.8 ± 3.1	0.06
Hemoglobin (g/dL)	13.0 ± 1.6	13.7 ± 1.2	0.08
Mean corpuscular volume (fL)	88.3 ± 4.1	87.6 ± 6.4	NS
ESR (mm/h)	30.8 ± 20.4	8.2 ± 2.8	<0.0001

Data are presented as means ± SD. AST, aspartate aminotransferase; ALT, alanine aminotransferase; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis. Bold *P* values are statistically significant.

taking non-steroidal anti-inflammatory drugs, 18 were taking prednisone, 16 were taking methotrexate, and 5 were taking gold. All patients had been taking the same medications for the 2 months preceding their entry into the study.

Patients and controls did not differ in the levels of serum albumin, creatinine, aspartate aminotransferase, and alanine aminotransferase. Patients had higher serum alkaline phosphatase levels, white blood cell counts and erythrocyte sedimentation rates than controls; patients also had a trend toward a reduced hematocrit, a smaller number of red blood cells and a lower hemoglobin level than the healthy control subjects (Table 2). Serum alkaline phosphatase concentration was inversely correlated with plasma pyridoxal 5'-phosphate concentration in all subjects (Pearson's correlation, $r = -0.35$, $P = 0.012$). In addition, serum albumin was modestly correlated with plasma pyridoxal 5'-phosphate in the patients (Pearson's correlation, $r = 0.37$, $P = 0.04$) but not in the control subjects.

Vitamin B₆ indices were altered in specific tissues during inflammation in humans with rheumatoid arthritis

In the human study, plasma pyridoxal 5'-phosphate concentrations were significantly lower in patients than in healthy sub-

jects (with about 50% lower). This observation was comparable to our previous finding [3]. In contrast, no difference was found between patients and controls in erythrocyte pyridoxal 5'-phosphate or erythrocyte aspartate aminotransferase or 4-pyridoxic acid levels. No difference was found in concentrations of plasma folate, red blood cell folate or plasma vitamin B₁₂ between patients and controls.

These results suggest that the lower vitamin B₆ concentration in patients with rheumatoid arthritis is tissue-specific.

Induction and progression of adjuvant arthritis in animals

Adjuvant arthritis was induced as described in the Materials and methods section. Arthritis onset was on day 14; the rats injected with adjuvant showed arthritic reactions including swollen paws and hind legs. Inflammation reached its peak on day 21 after the adjuvant injection. Joint swelling and body weight reduction continued for a further 4 weeks after the onset of arthritis (Table 1). Animals in the control and adjuvant groups were well matched in body weight at baseline before the induction of adjuvant arthritis.

Adjuvant arthritis altered vitamin B₆ contents in specific tissues in the Lewis rat model

At baseline before the adjuvant/saline injection, there was no difference between the adjuvant arthritis group and the saline-injected group in plasma concentrations of pyridoxal 5'-phosphate or urinary 4-pyridoxic acid excretion. These observations indicated that the animals were also well matched at baseline with regard to their vitamin B₆ status. From then on, each control animal received the same amount of food as its experimental counterpart ingested during the previous 24 hours; this pair-feeding procedure minimized the impact of various vitamin intakes between the adjuvant-treated and the control animals. Adjuvant arthritis reached its peak 21 days after the injection. At peak inflammation, significantly lower levels of pyridoxal 5'-phosphate were found in the circulation and in liver in those arthritis rats, but muscle pyridoxal 5'-phosphate concentration seemed to be unaltered. A lower level of pyridoxal 5'-phosphate was also present in the circulation and in liver during chronic inflammation on day 42. However, prolonged inflammation did not alter the muscle content of pyridoxal 5'-phosphate. Plasma pyridoxal 5'-phosphate concentration was correlated with hepatic pyridoxal 5'-phosphate content during peak (Pearson's correlation, $r = 0.51$, $P < 0.005$) and chronic ($r = 0.38$, $P < 0.04$) inflammation.

Adjuvant arthritis does not increase the urinary excretion of vitamin B₆ at peak inflammation or during the chronic phase of inflammation

Despite the significantly lower pyridoxal 5'-phosphate levels in plasma and liver at acute inflammation, we did not observe a significant change in urinary 4-pyridoxic acid or creatinine excretion, indicating that the low level of vitamin B₆ in plasma or liver at acute inflammation was not caused by excessive excretion of this vitamin. The 24-hour urinary excretion of 4-pyridoxic acid was highly correlated with the 24-hour urinary creatinine excretion throughout the study, indicating that renal function could be a significant determinant of 4-pyridoxic acid excretion in these animals. At baseline, 24-hour urinary 4-pyridoxic acid excretion was highly correlated with 24-hour urinary creatinine excretion in all rats (Pearson's correlation, $r = 0.85$, $P < 0.0001$). The 24-hour urinary excretion of 4-pyridoxic acid was correlated with 24-hour urinary creatinine excretion on day 21 (in control animals, $r = 0.615$, $P = 0.005$; in arthritic animals, $r = 0.617$, $P = 0.014$) and on day 42 (in control animals, $r = 0.78$, $P < 0.0001$; in arthritic animals, $r = 0.80$, $P < 0.0001$).

Discussion

The results of these rat and human studies indicate that inflammation directly affects vitamin B₆ metabolism differently in different tissues. Furthermore, the low vitamin B₆ level is unlikely to be due to a decrease in food intake or the excessive excretion of vitamin B₆. Adjuvant arthritis in Lewis rats is a useful animal model for studying vitamin B₆ status during inflammation. Adjuvant arthritis decreased the pyridoxal 5'-phosphate pools

in the circulation and liver, whereas it did not alter the pyridoxal 5'-phosphate pool in the skeletal muscle. Liver was studied because of its significant metabolic relevance and muscle was studied because it is the major store for vitamin B₆. The lower plasma pyridoxal 5'-phosphate concentration in arthritic animals during inflammation was found to be in the physiological range seen in humans with rheumatoid arthritis. Despite the limited number of human subjects, the difference between patients and controls in plasma pyridoxal 5'-phosphate concentration was significant. The average plasma pyridoxal 5'-phosphate concentration in patients with rheumatoid arthritis was about 55% of the level seen in the healthy controls. The mean pyridoxal 5'-phosphate concentration in rats with adjuvant arthritis was about 53% of the controls at peak inflammation on day 21. Rat adjuvant arthritis reflected the altered plasma pyridoxal 5'-phosphate and it is a potential model for studying vitamin B₆ status during inflammation.

Lumeng and colleagues suggested that plasma pyridoxal 5'-phosphate concentration reflects vitamin B₆ status in the liver in healthy humans [21]. Kinetic studies in rats also indicate that changes in plasma pyridoxal 5'-phosphate content primarily reflect changes in the relatively small, but metabolically relevant and more rapidly exchanging, liver pool (as compared with muscle) [22]. However it was not clear whether this is true during inflammation. The reduced plasma pyridoxal 5'-phosphate level in our study implies that vitamin B₆ status in the liver in these patients was altered, because we previously found good correlations between circulating pyridoxal 5'-phosphate level and vitamin B₆ functional status measured by methionine load and tryptophan load in these patients [14]. Results from adjuvant arthritis were in agreement with this postulation. In the rat arthritis model, both plasma and hepatic pyridoxal 5'-phosphate concentrations were lower (Table 3). Furthermore, plasma pyridoxal 5'-phosphate concentration was correlated with hepatic pyridoxal 5'-phosphate content. These results suggest that the lower circulating pyridoxal 5'-phosphate levels observed in rheumatoid arthritis could reflect a decrease in hepatic pyridoxal 5'-phosphate pools, and plasma pyridoxal 5'-phosphate is a good indicator of liver B₆ status during inflammation.

Our data imply that there are distinct metabolic roles for plasma and erythrocytes in vitamin B₆ metabolism during inflammation, and that the impact of inflammation on vitamin B₆ is tissue specific. In human subjects, despite the significantly lower pyridoxal 5'-phosphate in plasma (and possibly in liver), erythrocyte pyridoxal 5'-phosphate seemed to be adequate in patients with rheumatoid arthritis, because no difference was found between patients and healthy controls in the erythrocyte pyridoxal 5'-phosphate level or the activity coefficient of erythrocyte aspartate aminotransferase (Table 4). These observations are in agreement with the findings by Talwar and colleagues, which showed that pyridoxal 5'-phosphate

Table 3**Effects of adjuvant arthritis on B vitamin status during inflammation in rats**

Component	Adjuvant arthritis (n = 18)	Control (n = 20)	P
Baseline			
Plasma pyridoxal 5'-phosphate (nmol/L)	793.9 ± 191.3	744.2 ± 145.4	0.89
Urinary 4-pyridoxic acid (µg/d)	30.8 ± 17.3	30.0 ± 18.9	0.89
Acute inflammation			
Plasma pyridoxal 5'-phosphate (nmol/L)	252.0 ± 62.5	480.9 ± 144.0	<0.0001
Urinary 4-pyridoxic acid (µg/24 h)	27.7 ± 14.9	32.9 ± 17.2	0.249
Liver pyridoxal 5'-phosphate (nmol/g)	22.6 ± 1.7	27.4 ± 4.9	0.035
Skeletal muscle pyridoxal 5'-phosphate (nmol/g)	7.7 ± 1.8	7.2 ± 0.9	0.88
Chronic inflammation			
Plasma pyridoxal 5'-phosphate (nmol/L)	324.2 ± 91.6	393.7 ± 143.5	0.033
Urinary 4-pyridoxic acid (µg/24 h)	31.1 ± 11.8	27.1 ± 14.2	0.39
Liver pyridoxal 5'-phosphate (nmol/g)	21.1 ± 3.0	31.7 ± 4.7	0.0001
Muscle pyridoxal 5'-phosphate (nmol/g)	8.7 ± 4.8	6.4 ± 2.5	0.907

Data are presented as means ± SD. Day 21 represents the acute inflammation condition; day 42 represents the chronic inflammation condition. Bold P values are statistically significant.

Table 4**Indices of vitamin B status in patients with rheumatoid arthritis and control subjects**

Component	Patients (n = 33)	Controls (n = 17)	P
Plasma pyridoxal 5'-phosphate (nmol/L) ^a	24.7 (19.5–31.1)	46.2 (35.3–60.3)	0.001
Red blood cell pyridoxal 5'-phosphate (nmol/L packed red blood cells)	39.7 (34.2–45.2)	33.1 (24.4–41.7)	0.182
α _{EAST}	1.8 (1.8–1.9)	1.9 (1.8–2.1)	0.242
Urinary 4-pyridoxic acid (µg/day) ^a	0.8 (0.6–1.0)	1.1 (0.9–1.6)	0.08
Plasma folate (µg/L) ^a	10.2 (8.4–12.5)	9.5 (7.9–11.3)	0.185
Red blood cell folate (µg/L) ^a	302 (262–347)	274 (226–333)	0.404
Vitamin B ₁₂ (ng/L) ^a	434 (390–496)	398 (334–473)	0.371

Data are shown as geometric means and 95% confidence intervals. ^aData were log-transformed to achieve normality for statistical analysis. α_{EAST}, erythrocyte aspartate aminotransferase activity coefficient. Bold P values are statistically significant.

decreases in plasma but not erythrocytes during systemic inflammatory response [23].

Data from our animal model imply localized vitamin B₆ depletion during inflammation. Before the present study it was not clear how the pyridoxal 5'-phosphate pool in muscle might react to an inflammatory process. In rats with adjuvant arthritis, hepatic pyridoxal 5'-phosphate content was decreased, whereas muscle pyridoxal 5'-phosphate content remained unaltered, suggesting localized vitamin B₆ deficiency during inflammation.

Skeletal muscle seems to be less sensitive to vitamin B₆ deficiency in humans. In young healthy males receiving a defined diet restricted in vitamin B₆, the muscle content of vitamin B₆ is relatively resistant to vitamin B₆ deficiency, whereas plasma

pyridoxal 5'-phosphate is more sensitive to dietary vitamin B₆ depletion [24]. We conclude that liver and muscle have distinctive roles as the body undergoes metabolic changes; skeletal muscle, the body's major storage site of vitamin B₆, may turn over very slowly during inflammation.

Low vitamin B₆ status is unlikely to be due to lower intake or excessive excretion

Dietary intake is known to be a major determinant of vitamin B₆ status. The arthritic and control rats showed decreases in plasma pyridoxal 5'-phosphate from the baseline levels. This was partly due to a decrease in overall food intake in both groups. However, the different vitamin B₆ status observed between animals with adjuvant arthritis and control animals in the present study was not caused by different food intake between the two groups. Food intake of individual rats in the

arthritis group was recorded daily, then a one-to-one match (each rat with adjuvant arthritis had its own weight-matched, saline-injected control) in food intake was arranged. This pair-feeding regimen in our animal experiments minimized the confounding effects of anorexia on the measures of vitamin B₆.

Despite the significantly lower plasma pyridoxal 5'-phosphate in patients, 24-hour urinary 4-pyridoxic acid excretion in patients with rheumatoid arthritis did not differ from that of the healthy control subjects (Table 4). The low circulating pyridoxal 5'-phosphate level seen in these patients therefore did not result from excessive catabolism of vitamin B₆. This is in agreement with the observation in our animal model. The 24-hour urinary excretion of 4-pyridoxic acid did not differ between control and rats with adjuvant arthritis, despite lower pyridoxal 5'-phosphate levels in plasma and liver in the adjuvant arthritic rats. To summarize these observations, the abnormal vitamin B₆ status in rheumatoid arthritis results from the inflammatory process, and it is unlikely that it resulted from insufficient intake or excessive excretion of vitamin B₆.

Potential factors involved in the compartmentalization of pyridoxal 5'-phosphate during inflammation

In healthy populations, the variance in plasma pyridoxal 5'-phosphate can be explained to a great extent by vitamin intake, serum albumin, and alkaline phosphatase. The later two are physiological variables directly related to pyridoxal 5'-phosphate metabolism. In an elderly Dutch population it was reported that a combination of vitamin B₆ intake, alkaline phosphatase, alcohol consumption, and albumin accounted for 30 to 40% variance in plasma pyridoxal 5'-phosphate [25]. Serum albumin is an acute-phase reactant that decreases during the flaring of active arthritis [26]. As the major protein for pyridoxal 5'-phosphate transport in the circulation, albumin might protect pyridoxal 5'-phosphate from hydrolysis [27]. In the present study, serum albumin was found to be correlated with plasma pyridoxal 5'-phosphate in patients whereas no such correlation was detected in the control subjects. Lower albumin levels in patients with more active arthritis may partly contribute to the lower pyridoxal 5'-phosphate level in these patients, although further study is needed for this postulation.

Many patients with arthritis have been reported to have elevated alkaline phosphatase [28], including those in the present study. Although still in the normal range, mean serum alkaline phosphatase levels in our patients were 26% elevated compared with healthy control subjects. Alkaline phosphatase hydrolyzes the phosphorylated form of vitamin B₆ [29]; we therefore speculate that serum alkaline phosphatase could be another key determinant of the concentration of circulating vitamin B₆ coenzyme during inflammation. Alkaline phosphatase has been shown to regulate extracellular levels of pyridoxal 5'-phosphate in humans [30,31], and abnormal vitamin B₆ metabolism was found in alkaline phosphatase knock-out mice [32]. We found that the serum alkaline phosphatase level

was inversely correlated with the plasma pyridoxal 5'-phosphate level in our subjects, which indirectly supports the above hypothesis. Compartmentalization of pyridoxal 5'-phosphate has been reported in the acute-phase response, such as the acute phase of myocardial infarction [33]. Because erythrocyte pyridoxal 5'-phosphate level seem to be normal whereas plasma and hepatic pyridoxal 5'-phosphate levels are significantly lower during inflammation, pyridoxal 5'-phosphate might be compartmentalized between tissues. The elevated alkaline phosphatase during inflammation may facilitate the mobilization and uptake of B₆ vitamers, because vitamin B₆ is taken up by tissues primarily in the form of pyridoxal.

In contrast, elevated serum alkaline phosphatase or reduced albumin did not provide a satisfactory explanation for the lower plasma pyridoxal 5'-phosphate level in rheumatoid arthritis, because the presence of disease remained a significant determinant of plasma pyridoxal 5'-phosphate concentrations after adjustment for serum alkaline phosphatase and albumin concentrations [34]. The low plasma pyridoxal 5'-phosphate level in patients with rheumatoid arthritis may also be attributed to elevated pyridoxal phosphatase activity during inflammation. It has been reported that the decrease in plasma pyridoxal 5'-phosphate characteristically seen in cirrhosis may be related to a substantial elevation of hepatic pyridoxal 5'-phosphate phosphatase activity [35]. McCarty hypothesized that the pro-inflammatory cytokine interleukin-6 might stimulate the activity of pyridoxal phosphatase in hepatocytes, in these patients, and the elevated enzyme may result in reduced plasma pyridoxal 5'-phosphate concentrations [36].

It remains uncertain whether the activity of pyridoxal 5'-phosphate phosphatase is altered in patients with arthritis, and this should be considered for future studies.

Conclusion

A lower pyridoxal 5'-phosphate concentration in the circulation may reflect the removal of vitamin B₆ coenzymes from the circulation to meet the higher demands of certain tissues during inflammation. In the animal model of adjuvant arthritis, lower pyridoxal 5'-phosphate levels in liver implied that it was largely hepatic pyridoxal 5'-phosphate that was used during inflammation. Further studies investigating the kinetics and regulation of B₆ vitamers and enzymes in different body compartments are merited.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

All authors made substantive intellectual contributions to the present study. EPC conceived of the study, acquired partial funding, performed the human and animal experiments – including study designs, coordination, biochemical analyses, data acquisition, analysis, and interpretation – and drafted the

manuscript. DES participated in the design and procedures of animal experiments. JS participated in the design of the study and the acquisition of funding, and was involved in revising the manuscript critically for important intellectual content. GED participated in the design of the study and performed the statistical analysis. YCW performed the animal experiments and analyses of metabolites. RR conceived of the study, acquired funding, and performed all clinical assessments in study subjects, and revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements

The authors thank Bernadette Muldoon RN, Karin Kohin RD, and Sarah Olson RD for their assistance in recruiting, and thank Dr Pamela Bagley for general support and supervision. Thanks are also given to Marie Nadeau for technical assistance, and the staff at the Human Nutrition Research Center Nutrition Evaluation Laboratory and the Tufts New England Medical Center Clinical Laboratory for hematology and chemistry analyses; to the General Clinical Research Center nursing staff for assistance with the study procedures; and to our volunteers. This project has been supported in part by a grant from the National Science Council of Taiwan (Grant # NSC 94-2320-B005-009; to E-PC). E-PC is a recipient of Dissertation Award from the Arthritis Foundation in the US. This project was also supported by the US Department of Agriculture under cooperative agreement no. 58-1950-9-001. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the US Department of Agriculture. This study was also supported in part by grant RR-00054 from the National Center for Research Resources, for the General Clinical Research Center, New England Medical Center and Tufts University School of Medicine (to RR).

References

- Mason JB, Miller JW: **The effects of vitamins B12, B6, and folate on blood homocysteine levels.** *Ann N Y Acad Sci* 1992, **669**:197-203.
- Rinehart JF, Greenberg LD: **Vitamin B6 deficiency in the rhesus monkey; with particular reference to the occurrence of atherosclerosis, dental caries, and hepatic cirrhosis.** *Am J Clin Nutr* 1956, **4**:318-325.
- Roubenoff R, Roubenoff RA, Selhub J, Nadeau MR, Cannon JG, Freeman LM, Dinarello CA, Rosenberg IH: **Abnormal vitamin B6 status in rheumatoid cachexia. Association with spontaneous tumor necrosis factor alpha production and markers of inflammation.** *Arthritis Rheum* 1995, **38**:105-109.
- Chiang EP, Bagley PJ, Selhub J, Nadeau M, Roubenoff R: **Abnormal vitamin B6 status is associated with severity of symptoms in patients with rheumatoid arthritis.** *Am J Med* 2003, **114**:283-287.
- Bates CJ, Pentieva KD, Prentice A, Mansoor MA, Finch S: **Plasma pyridoxal phosphate and pyridoxic acid and their relationship to plasma homocysteine in a representative sample of British men and women aged 65 years and over.** *Br J Nutr* 1999, **81**:191-201.
- Cattaneo M: **Hyperhomocysteinemia: a risk factor for arterial and venous thrombotic disease.** *Int J Clin Lab Res* 1997, **27**:139-144.
- Ridker PM, Hennekens CH, Buring JE, Rifai N: **C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.** *N Engl J Med* 2000, **342**:836-843.
- Lakshmi R, Lakshmi AV, Divan PV, Bamji MS: **Effect of riboflavin or pyridoxine deficiency on inflammatory response.** *Indian J Biochem Biophys* 1991, **28**:481-484.
- Folsom AR, Desvarieux M, Nieto FJ, Boland LL, Ballantyne CM, Chambless LE: **B vitamin status and inflammatory markers.** *Atherosclerosis* 2003, **169**:169-174.
- Friso S, Jacques PF, Wilson PW, Rosenberg IH, Selhub J: **Low circulating vitamin B6 is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels.** *Circulation* 2001, **103**:2788-2791.
- Friso S, Girelli D, Martinelli N, Olivieri O, Lottio V, Bozzini C, Pizzolo F, Faccini G, Beltrame F, Corrocher R: **Low plasma vitamin B-6 concentrations and modulation of coronary artery disease risk.** *Am J Clin Nutr* 2004, **79**:992-998.
- Labadarios D, Brink PA, Weich HF, Visser L, Louw ME, Shephard GS, van Stuijvenberg ME: **Plasma vitamin A, E, C and B6 levels in myocardial infarction.** *S Afr Med J* 1987, **71**:561-563.
- Saibeni S, Cattaneo M, Vecchi M, Zighetti ML, Lecchi A, Lombardi R, Meucci G, Spina L, de Franchis R: **Low vitamin B6 plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants.** *Am J Gastroenterol* 2003, **98**:112-117.
- Chiang EP, Bagley PJ, Roubenoff R, Nadeau M, Selhub J: **Plasma pyridoxal 5'-phosphate concentration is correlated with functional vitamin B-6 indices in patients with rheumatoid arthritis and marginal vitamin B-6 status.** *J Nutr* 2003, **133**:1056-1059.
- Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F: **The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis.** *Arthritis Rheum* 1992, **35**:498-502.
- Paulini K, Korner B, Mohr W, Sonntag W: **The effect of complete Freund-adjuvant on chronic proliferating inflammation in an experimental granuloma model.** *Z Rheumatol* 1976, **35**:123-131.
- Williams DG: **Methods for the estimation of three vitamin dependent red cell enzymes.** *Clin Biochem* 1976, **9**:252-255.
- Camp VM, Chipponi J, Faraj BA: **Radioenzymatic assay for direct measurement of plasma pyridoxal 5'-phosphate.** *Clin Chem* 1983, **29**:642-644.
- Gregory JF 3rd, Kirk JR: **Determination of urinary 4-pyridoxic acid using high performance liquid chromatography.** *Am J Clin Nutr* 1979, **32**:879-883.
- Heiskanen K, Siimes MA, Perheentupa J, Salmenpera L: **Reference ranges for erythrocyte pyridoxal 5'-phosphate concentration and the erythrocyte aspartate transaminase stimulation test in lactating mothers and their infants.** *Am J Clin Nutr* 1994, **59**:1297-1303.
- Lumeng L, Lui A, Li TK: **Plasma content of B6 vitamers and its relationship to hepatic vitamin B6 metabolism.** *J Clin Invest* 1980, **66**:688-695.
- Bode W, Mocking JA, van den Berg H: **Influence of age and sex on vitamin B-6 vitamers distribution and on vitamin B-6 metabolizing enzymes in Wistar rats.** *J Nutr* 1991, **121**:318-329.
- Talwar D, Quasim T, McMillan DC, Kinsella J, Williamson C, O'Reilly DS: **Pyridoxal phosphate decreases in plasma but not erythrocytes during systemic inflammatory response.** *Clin Chem* 2003, **49**:515-518.
- Coburn SP, Ziegler PJ, Costill DL, Mahuren JD, Fink WJ, Schaltenbrand WE, Pauly TA, Pearson DR, Conn PS, Guilarte TR: **Response of vitamin B-6 content of muscle to changes in vitamin B-6 intake in men.** *Am J Clin Nutr* 1991, **53**:1436-1442.
- Brussaard JH, Lowik MR, van den BH, Brants HA, Bemelmans W: **Dietary and other determinants of vitamin B6 parameters.** *Eur J Clin Nutr* 1997, **51**(Suppl 3):S39-S45.
- Denko CW, Gabriel P: **Serum proteins - transferrin, ceruloplasmin, albumin, alpha 1-acid glycoprotein, alpha 1-antitrypsin - in rheumatic disorders.** *J Rheumatol* 1979, **6**:664-672.
- Lumeng L, Brashear RE, Li TK: **Pyridoxal 5'-phosphate in plasma: source, protein-binding, and cellular transport.** *J Lab Clin Med* 1974, **84**:334-343.
- Aida S: **Alkaline phosphatase isoenzyme activities in rheumatoid arthritis: hepatobiliary enzyme dissociation and relation to disease activity.** *Ann Rheum Dis* 1993, **52**:511-516.
- Lumeng L, Li TK: **Characterization of the pyridoxal 5'-phosphate and pyridoxamine 5'-phosphate hydrolase activity in rat liver. Identity with alkaline phosphatase.** *J Biol Chem* 1975, **250**:8126-8131.
- Whyte MP, Mahuren JD, Vrabel LA, Coburn SP: **Markedly increased circulating pyridoxal-5'-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism.** *J Clin Invest* 1985, **76**:752-756.

31. Anderson BB, O'Brien H, Griffin GE, Mollin DL: **Hydrolysis of pyridoxal-5'-phosphate in plasma in conditions with raised alkaline phosphate.** *Gut* 1980, **21**:192-194.
32. Narisawa S, Wennberg C, Millan JL: **Abnormal vitamin B6 metabolism in alkaline phosphatase knock-out mice causes multiple abnormalities, but not the impaired bone mineralization.** *J Pathol* 2001, **193**:125-133.
33. Vermaak WJ, Barnard HC, Van Dalen EM, Potgieter GM, Van Jaarsveld H, Myburgh SJ: **Compartmentalization of pyridoxal-5'-phosphate during the acute phase of myocardial infarction.** *Klin Wochenschr* 1988, **66**:428-433.
34. Chiang EP: **Vitamin B6 and homocysteine metabolism in rheumatoid arthritis.** In *PhD thesis* Tufts University, Nutritional Science Department; 2000.
35. Merrill AH Jr, Henderson JM, Wang E, Codner MA, Hollins B, Millikan WJ: **Activities of the hepatic enzymes of vitamin B6 metabolism for patients with cirrhosis.** *Am J Clin Nutr* 1986, **44**:461-467.
36. McCarty MF: **Increased homocyst(e)ine associated with smoking, chronic inflammation, and aging may reflect acute-phase induction of pyridoxal phosphatase activity.** *Med Hypotheses* 2000, **55**:289-293.